Chart of Day: Mersana Therapeutics (MRSN) – 2/3

Mersana Therapeutics (MRSN) is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options.

There are a few reasons to get bullish on Mersana Therapeutics.


For one, according to Pfizer’s CEO Albert Bourla, ADCs have become one of the hottest opportunities in oncology, which would explain why it recently acquired Seagen for $34 billion. Even better, Pfizer wants to acquire even more ADC companies.

Two, Citi analysts recently upgraded MRSN to a Buy with a price target of $5. Given the accelerating M&A activity in the broader ADC space, the firm believes the market will be receptive to revisiting Mersana, notes

Three, the company is advancing its Phase 1 clinical trial of XMT-1660, the company’s lead Dolasynthen ADC candidate targeting B7-H4.  According to Cell Immunology, B7-H4 negatively regulates T cell immune response and promotes immune escape by inhibiting the proliferation, cytokine secretion, and cell cycle of T cells.”

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.